Uveitis - Pipeline Review, H1 2016

Date: April 20, 2016
Pages: 203
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: U8BD67BCFFDEN
Leaflet:

Download PDF Leaflet

Uveitis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Uveitis - Pipeline Review, H1 2016’, provides an overview of the Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Uveitis
  • The report reviews pipeline therapeutics for Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Uveitis therapeutics and enlists all their major and minor projects
  • The report assesses Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Uveitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Uveitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Uveitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Uveitis Overview
Therapeutics Development
Pipeline Products for Uveitis – Overview
Pipeline Products for Uveitis – Comparative Analysis
Uveitis – Therapeutics under Development by Companies
Uveitis – Therapeutics under Investigation by Universities/Institutes
Uveitis – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Uveitis – Products under Development by Companies
Uveitis – Products under Investigation by Universities/Institutes
Uveitis – Companies Involved in Therapeutics Development
2-BBB MEDICINES BV
AbbVie Inc.
Aciont Inc.
Aldeyra Therapeutics, Inc.
Apitope International NV
Astellas Pharma Inc.
Bausch & Lomb Incorporated
Bionomics Limited
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Clearside BioMedical, Inc.
Effimune SAS
Endocyte, Inc.
Enzo Biochem, Inc.
EyeGate Pharmaceuticals, Inc.
HanAll Biopharma Co., Ltd.
Icon Bioscience, Inc.
Johnson & Johnson
Kineta, Inc.
Mitotech S.A.
Neuroptis Biotech
Novartis AG
Oculis ehf
OncoNOx ApS
Palatin Technologies, Inc.
Panoptes Pharma Ges.m.b.H.
Pfizer Inc.
Precision Ocular Ltd
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SynDevRx, Inc.
ThromboGenics NV
TxCell SA
Virogenomics BioDevelopment, Inc.
Uveitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
2-B3201 - DRUG PROFILE
abatacept - Drug Profile
adalimumab - Drug Profile
ANV-103 - Drug Profile
ATXUV-1 - Drug Profile
ATXUV-2 - Drug Profile
B27-PD - Drug Profile
BNC-164 - Drug Profile
celecoxib - Drug Profile
Col-Treg - Drug Profile
CVX-001 - Drug Profile
cyclosporine SR - Drug Profile
Cytectin - Drug Profile
dalazatide - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone sodium phosphate - Drug Profile
Drug for Chronic Uveitis - Drug Profile
Drugs for Retinal Diseases - Drug Profile
Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile
EC-1669 - Drug Profile
fluocinolone acetonide - Drug Profile
fluocinolone acetonide SR - Drug Profile
FR-104 - Drug Profile
HL-036 - Drug Profile
INV-17 - Drug Profile
IVMED-20 - Drug Profile
KPI-190 - Drug Profile
LME-636 - Drug Profile
lodamin - Drug Profile
methotrexate - Drug Profile
NOP-3 - Drug Profile
NS-2 - Drug Profile
OX-1001 - Drug Profile
PA-2612 - Drug Profile
piclidenoson - Drug Profile
PL-8177 - Drug Profile
plastoquinone decyl triphenylphosphonium bromide - Drug Profile
PP-001 - Drug Profile
PPL-003 - Drug Profile
Recombinant Enzymes for Uveitis - Drug Profile
Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile
sarilumab - Drug Profile
sirolimus - Drug Profile
Small Molecules to Inhibit 5-lipoxygenase for Uveitis - Drug Profile
Stem Cell Therapy for Autoimmune Diseases - Drug Profile
tesidolumab - Drug Profile
TG-931 - Drug Profile
TOP-1288 - Drug Profile
triamcinolone acetonide - Drug Profile
triamcinolone acetonide - Drug Profile
Uveitis – Recent Pipeline Updates
Uveitis - Dormant Projects
Uveitis – Discontinued Products
Uveitis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Uveitis, H1 2016
Number of Products under Development for Uveitis – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2016
Uveitis – Pipeline by 2-BBB Medicines BV, H1 2016
Uveitis – Pipeline by AbbVie Inc., H1 2016
Uveitis – Pipeline by Aciont Inc., H1 2016
Uveitis – Pipeline by Aldeyra Therapeutics, Inc., H1 2016
Uveitis – Pipeline by Apitope International NV, H1 2016
Uveitis – Pipeline by Astellas Pharma Inc., H1 2016
Uveitis – Pipeline by Bausch & Lomb Incorporated, H1 2016
Uveitis – Pipeline by Bionomics Limited, H1 2016
Uveitis – Pipeline by Bristol-Myers Squibb Company, H1 2016
Uveitis – Pipeline by Can-Fite BioPharma Ltd., H1 2016
Uveitis – Pipeline by Clearside BioMedical, Inc., H1 2016
Uveitis – Pipeline by Effimune SAS, H1 2016
Uveitis – Pipeline by Endocyte, Inc., H1 2016
Uveitis – Pipeline by Enzo Biochem, Inc., H1 2016
Uveitis – Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016
Uveitis – Pipeline by HanAll Biopharma Co., Ltd., H1 2016
Uveitis – Pipeline by Icon Bioscience, Inc., H1 2016
Uveitis – Pipeline by Johnson & Johnson, H1 2016
Uveitis – Pipeline by Kineta, Inc., H1 2016
Uveitis – Pipeline by Mitotech S.A., H1 2016
Uveitis – Pipeline by Neuroptis Biotech, H1 2016
Uveitis – Pipeline by Novartis AG, H1 2016
Uveitis – Pipeline by Oculis ehf, H1 2016
Uveitis – Pipeline by OncoNOx ApS, H1 2016
Uveitis – Pipeline by Palatin Technologies, Inc., H1 2016
Uveitis – Pipeline by Panoptes Pharma Ges.m.b.H., H1 2016
Uveitis – Pipeline by Pfizer Inc., H1 2016
Uveitis – Pipeline by Precision Ocular Ltd, H1 2016
Uveitis – Pipeline by pSivida Corp., H1 2016
Uveitis – Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Uveitis – Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
Uveitis – Pipeline by SynDevRx, Inc., H1 2016
Uveitis – Pipeline by ThromboGenics NV, H1 2016
Uveitis – Pipeline by TxCell SA, H1 2016
Uveitis – Pipeline by Virogenomics BioDevelopment, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Uveitis Therapeutics – Recent Pipeline Updates, H1 2016
Uveitis – Dormant Projects, H1 2016
Uveitis – Dormant Projects (Contd..1), H1 2016
Uveitis – Dormant Projects (Contd..2), H1 2016
Uveitis – Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Uveitis, H1 2016
Number of Products under Development for Uveitis – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016
Skip to top


Anterior Uveitis - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 59 pages
Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 194 pages
Anterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 55 pages
Posterior Uveitis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 65 pages
Posterior Uveitis - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 64 pages

Ask Your Question

Uveitis - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: